Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations
- Author
- GUZMAN, Hector R1 ; TAWA, Mark1 ; ZHONG ZHANG1 ; RATANABANANGKOON, Pasut1 ; SHAW, Paul1 ; GARDNER, Colin R1 ; HONGMING CHEN1 ; MOREAU, Jean-Pierre2 ; ALMARSSON, Örn1 ; REMENAR, Julius F1
[1] TransForm Pharmaceuticals, Inc., 29 Hartwell Avenue, Lexington, Massachusetts 02421, United States
[2] MDS Pharma Services, Montreal, Canada - Source
Journal of pharmaceutical sciences. 2007, Vol 96, Num 10, pp 2686-2702, 17 p ; ref : 26 ref
- CODEN
- JPMSAE
- ISSN
- 0022-3549
- Scientific domain
- Pharmacology drugs
- Publisher
- American Pharmaceutical Association, Washington, DC
/
Wiley, Hoboken, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- bioavailability crystallinity dissolution formulation in vitro/in vivo correlations (IVIVC) oral drug delivery pharmacokinetics supersaturation
- Keyword (fr)
- Absorption Antiinflammatoire non stéroïde Biodisponibilité Corrélation Cristallinité Célécoxib Dissolution Forme cristalline Formulation In vitro In vivo Médicament Pharmacocinétique Précipitation Sursaturation Technologie pharmaceutique Voie orale Enzyme Inhibiteur cyclooxygenase 2 Inhibiteur enzyme Oxidoreductases Prostaglandin-endoperoxide synthase
- Keyword (en)
- Absorption Non steroidal antiinflammatory agent Bioavailability Correlation Crystallinity Celecoxib Dissolution Crystal form Formulation In vitro In vivo Drug Pharmacokinetics Precipitation Supersaturation Pharmaceutical technology Oral administration Enzyme Cyclooxygenase 2 inhibitor Enzyme inhibitor Oxidoreductases Prostaglandin-endoperoxide synthase
- Keyword (es)
- Absorción Antiinflamatorio no esteroide Biodisponibilidad Correlación Cristalinidad Celecoxib Disolución Forma cristalina Formulación In vitro In vivo Medicamento Farmacocinética Precipitación Sobresaturación Tecnología farmacéutica Vía oral Enzima Inhibidor cyclooxygenase 2 Inhibidor enzima Oxidoreductases Prostaglandin-endoperoxide synthase
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A03 Pharmaceutical technology. Pharmaceutical industry
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19135037
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/jps.20906 
https://dx.doi.org/10.1002/jps.20906
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/jps.20906\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:9:\"\u0000*\u0000jtitle\";s:34:\"Journal of pharmaceutical sciences\";s:9:\"\u0000*\u0000stitle\";s:13:\"J. pharm. sci\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"96\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2686\";s:8:\"\u0000*\u0000epage\";s:4:\"2702\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-3549\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GUZMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Hector R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"TAWA, Mark\";i:1;s:11:\"ZHONG ZHANG\";i:2;s:23:\"RATANABANANGKOON, Pasut\";i:3;s:10:\"SHAW, Paul\";i:4;s:16:\"GARDNER, Colin R\";i:5;s:13:\"HONGMING CHEN\";i:6;s:19:\"MOREAU, Jean-Pierre\";i:7;s:15:\"ALMARSSON, \u00d6rn\";i:8;s:17:\"REMENAR, Julius F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JPMSAE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"American Pharmaceutical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/jps.20906\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:9:\"\u0000*\u0000jtitle\";s:34:\"Journal of pharmaceutical sciences\";s:9:\"\u0000*\u0000stitle\";s:13:\"J. pharm. sci\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"96\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2686\";s:8:\"\u0000*\u0000epage\";s:4:\"2702\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-3549\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GUZMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Hector R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"TAWA, Mark\";i:1;s:11:\"ZHONG ZHANG\";i:2;s:23:\"RATANABANANGKOON, Pasut\";i:3;s:10:\"SHAW, Paul\";i:4;s:16:\"GARDNER, Colin R\";i:5;s:13:\"HONGMING CHEN\";i:6;s:19:\"MOREAU, Jean-Pierre\";i:7;s:15:\"ALMARSSON, \u00d6rn\";i:8;s:17:\"REMENAR, Julius F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JPMSAE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"American Pharmaceutical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/jps.20906\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/jps.20906\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:9:\"\u0000*\u0000jtitle\";s:34:\"Journal of pharmaceutical sciences\";s:9:\"\u0000*\u0000stitle\";s:13:\"J. pharm. sci\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"96\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2686\";s:8:\"\u0000*\u0000epage\";s:4:\"2702\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-3549\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GUZMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Hector R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"TAWA, Mark\";i:1;s:11:\"ZHONG ZHANG\";i:2;s:23:\"RATANABANANGKOON, Pasut\";i:3;s:10:\"SHAW, Paul\";i:4;s:16:\"GARDNER, Colin R\";i:5;s:13:\"HONGMING CHEN\";i:6;s:19:\"MOREAU, Jean-Pierre\";i:7;s:15:\"ALMARSSON, \u00d6rn\";i:8;s:17:\"REMENAR, Julius F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JPMSAE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"American Pharmaceutical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1002\/jps.20906\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:9:\"\u0000*\u0000jtitle\";s:34:\"Journal of pharmaceutical sciences\";s:9:\"\u0000*\u0000stitle\";s:13:\"J. pharm. sci\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"96\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2686\";s:8:\"\u0000*\u0000epage\";s:4:\"2702\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-3549\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"GUZMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Hector R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"TAWA, Mark\";i:1;s:11:\"ZHONG ZHANG\";i:2;s:23:\"RATANABANANGKOON, Pasut\";i:3;s:10:\"SHAW, Paul\";i:4;s:16:\"GARDNER, Colin R\";i:5;s:13:\"HONGMING CHEN\";i:6;s:19:\"MOREAU, Jean-Pierre\";i:7;s:15:\"ALMARSSON, \u00d6rn\";i:8;s:17:\"REMENAR, Julius F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JPMSAE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:136:\"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"American Pharmaceutical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
